Paul Matteis

Shares of Neumora Therapeutics Inc (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange. RBC Capital Markets On Neumora Therapeutics Analyst Brian Abrahams initiated coverage with an Outperform rating and price target of $24. Neumora...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) said late Monday it was notified by the Food and Drug Administration of deficiencies in its regulatory application to expand the label for pimavanserin, which goes by the brand name Nuplazid. The company is seeking approval for Nuplazid as a...

After a huge year in 2017, GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) stock has traded mostly sideways so far in 2018. But one analysts believes GW will soon return to its winning ways. The Analyst Stifel analyst Paul Matteis initiated coverage of GW Pharma with a Buy rating and $181 price target....

The Street leans bullish on Biogen Inc (NASDAQ: BIIB), and one sidelined analyst doesn’t want to miss on the profits. The Rating Stifel Nicolaus analyst Paul Matteis resumed coverage of Biogen with a Buy rating and $394 price target. The Thesis Biogen’s fate is seen to hinge...

Neurocrine Biosciences, Inc. (NASDAQ: NBIX), which already has two strong drugs in the market in the form of Ingrezza and the recently approved elagolix, has a promising pipeline ahead, according to Stifel.  The Analyst Analyst Paul Matteis initiated coverage of Neurocrine with a Buy rating...

Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) is set to release its second-quarter earnings report after the bell Tuesday, and Stifel reviewed the stock ahead of the print.  The Analysts Stifel analyst Paul Matteis initiated coverage of Alder BioPharmaceuticals with a Buy rating and $30 price...

It’s earnings season, and a steady stream of financial figures are separating the flawed from the flourishing in the pharmaceutical sector.  The Ratings Leerink reiterated Outperform ratings on the following stocks: Zogenix, Inc. (NASDAQ: ZGNX), with a price target increase from $...

With a balanced take on many newsworthy items regarding ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) released Wednesday, Leerink reiterated its Market Perform rating on the shares of the company. At time of publication, shares of Acadia Pharma were up 1.12 percent at $38.73 in Friday's pre-...

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) shares fell sharply Wednesday following a disappointing phase 2 study of Ingrezza (valbenazine), a pediatric Tourette's syndrome drug. The company announced after Tuesday's close that Ingrezza didn't show a statistically significant difference on...

The FDA has approved Spinraza for the treatment of all types of spinal muscular atrophy. The approval comes six months earlier than expected and with a label that is “as broad as even the most optimistic patient or investor could have hoped for,” Leerink’s Geoffrey C. Porges said...

Leerink resumed coverage on GW Pharmaceuticals PLC (NASDAQ: GWPH) in anticipation of FDA approval for Epidiolex. Analyst Paul Matteis expressed an Outperform Rating, and set the firm’s price target at $162. Matteis primarily cited the FDA’s pending approval of Epidiolex, and...